
Nanobiotix SA licences NBTXR3 to J&J
NBTXR3 is currently being evaluated across different solid tumour indications including NANORAY‑312, a global Phase III pivotal study in ...

Mithra raises €20m through private placement
Under the terms of the Private Placement, Armistice Capital committed to subscribe for 10 million new shares atz a share price of 2€ per share , of...

Promising viral gene therapy for genetic kidney disease
UK resesearchers have engineered an adeno-associated virus vector to treat the heriditary steroid-resistant nephrotic syndrome in children, which is...

Study: New breeding methods hardly contribute to climate protection
Up and down the country, national governments and the EU Commission (EC) are campaigning to facilitate the commercialisation of cis-gentic and...

Seed money for unique topical hair growth inducer
Good news for all those with genetic hormonal hair loss (androgenic alopecia and Alopecia areata): according to the patent specification, an...

Resistance blocker of immune checkpoint inhibitors gets patented
DT-9081, Domain Therapeutics’ selective EP4 receptor antagonist, preclinically synergised with PD1-checkpoint blockers and shrinked tumours by...